查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1520462

2024-2032 年按技术、生物材料、应用和地区分類的神经调节市场报告

Neuromodulation Market Report by Technology, Biomaterial, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球神经调节市场规模达74亿美元。在强劲投资的支持下，慢性疾病和神经系统疾病的盛行率不断上升、有利的监管环境、医疗保健支出不断增加、设备技术的显着进步以及对微创(MI) 疗法的需求不断增长，推动了该市场正在经历强劲增长研究与开发 (R&D) 计划。

神经调节市场分析：

主要市场驱动因素：神经调节市场是由慢性疾病和神经系统疾病（如帕金森氏症、慢性疼痛和忧郁症）日益普及所驱动。此外，医疗保健支出的不断增加、改善报销政策的有利法规的实施以及神经调节设备的快速技术进步（包括磁振造影（MRI）安全和可充电设备的开发）正在推动市场成长。

主要市场趋势：目前有一种趋势是将人工智慧 (AI) 和机器学习 (ML) 技术整合到神经调节设备中，以实现即时监测和调整治疗。此外，在正在进行的研究和成功的临床试验的推动下，神经调节疗法适应症的扩大正在扩大市场的规模。

地理趋势：北美因其先进的医疗基础设施、健全的监管框架和高昂的医疗支出而在神经调节市场占据主导地位。在医疗基础设施改善、可支配收入增加以及对神经调节疗法认识不断增强的推动下，其他地区也在经历快速增长。

竞争格局：神经调节产业的一些主要市场参与者包括 Abbott Laboratories、Bioventus Inc.、Boston Scientific Corporation、Helius Medical Technologies、Integer Holdings Corporation、LivaNova PLC、Medtronic plc、MicroTransponder Inc.、Neuronetics、NeuroPace Inc.、NeuroSigma Inc .、Nevro Corp. 等。

挑战和机会：主要挑战是设备和程序的高成本，这可能限制市场渗透，特别是在发展中地区。此外，设备植入的复杂性和潜在的副作用也构成了障碍。然而，机会在于神经调节应用范围的扩大，包括针对肥胖和成瘾等尚未开发的医疗状况的潜在治疗方法。此外，医疗保健支出的增加为市场扩展到以前服务不足的地区提供了重要机会。

神经调节市场趋势：

慢性病和神经系统疾病的盛行率上升

糖尿病、肥胖症和心血管疾病等慢性疾病以及帕金森氏症、癫痫和忧郁症等神经系统疾病的发生率上升，是神经调节市场的重要驱动力。根据疾病管制与预防中心 (CDC) 的数据，美国十分之六的成年人患有慢性病。十分之四的人患有两种以上的慢性病。此外，印度约 21% 的老年人患有至少一种慢性病。农村地区 17% 的老年人和城市地区 29% 的老年人患有至少一种慢性病。这些健康问题会导致併发症，但可以透过神经调节疗法来控製或治疗。例如，脊髓刺激 (SCS) 广泛用于缓解背部手术失败症候群或复杂区域疼痛症候群引起的疼痛。

医疗保健支出增加

由于医疗保健支出不断增加、中产阶级人口不断增长以及先进医疗基础设施的建立，全球多个国家越来越多地采用神经调节疗法。例如，印度医疗保健公共支出在 2023 财年占 GDP 的 2.1%，在 2022 财年占 GDP 的 2.2%。此外，印度政府还计划推出价值卢比的信贷奖励计画。 5000 亿卢比（68 亿美元）用于加强该国的医疗基础设施。同样，在欧洲，2022 年政府整体医疗支出达到 12,210 亿欧元，占 GDP 的 7.7%。这种扩张正在扩大神经调节产业的地理足迹，并将这些先进的疗法引入新的患者群体。

落实优惠报销政策

神经调节手术报销政策的持续改善是推动市场成长的主要因素。在许多国家，健康保险公司已经修改了他们的政策，将几种神经调节疗法纳入其中，因为他们认识到神经调节疗法在治疗许多难治性疾病方面的益处。这些变化使神经调节技术更容易为更广泛的患者所使用。根据美国人口普查局的数据，到 2022 年，美国 92.1% 的人（即 3.040 亿人）在一年中的某个时候拥有健康保险。此外，私人医疗保险覆盖率比公共医疗保险覆盖率更高，分别为 65.6% 和 36.1%。此外，保险公司正在认识到神经调节的长期成本效益，特别是在减少住院时间和药物使用方面，这正在扩大报销范围。

神经调节市场细分：

IMARC Group提供了每个细分市场的主要趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据技术、生物材料和应用对市场进行了分类。

按技术划分：

内部神经调节

脊髓刺激 (SCS)

深部脑部刺激 (DBS)

迷走神经刺激 (VNS)

荐神经刺激 (SNS)

胃电刺激 (GES)

外部神经调节

经皮电神经刺激 (TENS)

经颅磁刺激 (TMS)

其他的

内部神经调节占据大部分市场份额

该报告基于该技术对市场进行了详细的细分和分析。这包括内部神经调节（脊髓刺激（SCS）、深部脑部刺激（DBS）、迷走神经刺激（VNS）、骶神经刺激（SNS）和胃电刺激（GES））和外部神经调节（经皮神经电刺激） TENS）、经颅磁刺激（TMS）等）。根据该报告，内部神经调节代表了最大的部分。

根据神经调节市场分析和预测，内部神经调节成为最大的细分市场。它包括先进的疗法，例如脊髓刺激（SCS）、深部脑部刺激（DBS）、骶神经刺激（SNS）和迷走神经刺激（VNS）等。它们用于治疗多种慢性病和神经系统疾病，包括慢性疼痛、帕金森氏症、尿失禁和大便失禁以及难治性癫痫。此外，内部神经调节在改善患者治疗效果方面的有效性已得到证实，设备技术的显着进步提高了使用者的安全性和舒适度，以及临床应用范围的扩大正在推动神经调节市场的收入。

依生物材料分类：

金属生物材料

高分子生物材料

陶瓷生物材料

金属生物材料产业占比最大

报告还提供了基于生物材料的市场的详细细分和分析。这包括金属生物材料、聚合生物材料和陶瓷生物材料。报告称，金属生物材料占据最大的市场份额。

根据神经调节市场报告和概述，金属生物材料脱颖而出，成为最大的细分市场，因为它们在神经调节治疗中使用的植入物和设备（例如电极和导线）的製造中发挥关键作用。金属生物材料因其卓越的导电性、生物相容性和耐用性而受到青睐。它们对于确保神经调节装置的长期可靠性和性能至关重要，特别是那些需要长期植入或受到体液和组织影响的装置。除此之外，提高其功能和安全性的持续进步，例如增强生物相容性的涂层或降低感染风险的技术，有利于神经调节市场的成长。

按应用划分：

帕金森氏症

癫痫

沮丧

肌张力失调

疼痛管理

其他的

帕金森氏症代表领先的细分市场

该报告根据应用程式提供了详细的市场细分和分析。这包括帕金森氏症、癫痫、忧郁症、肌张力失调、疼痛管理等。根据该报告，帕金森氏症占最大部分。

根据神经调节市场前景和趋势，帕金森氏症成为最大的细分市场，反映了神经调节疗法在治疗慢性神经疾病方面的重大影响和效用。越来越多地使用深部脑部刺激（DBS）来治疗对药物治疗没有充分反应的患者，这促进了市场的成长。 DBS有助于缓解震颤、僵硬和运动迟缓等症状，显着提高患者的生活品质。此外，神经调节在提供实质和持续的症状缓解方面的功效，导致其在临床环境中的广泛采用，正在促进神经调节的市场份额。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场领先，占据最大的神经调节市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是神经调节最大的区域市场。

北美占据了神经调节市场最大的份额，这归因于几个关键因素，包括先进的医疗基础设施、强有力的监管支持以及对研发 (R&D) 的大量投资。此外，该地区是神经调节行业中一些领先公司的中心，透过不断的技术进步推动创新和市场成长。此外，慢性病和神经系统疾病的高盛行率，加上有利于早期采用新技术的完善的医疗保健系统，正在为神经调节市场收入做出贡献。

竞争格局：

市场研究报告也对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。神经调节产业的一些主要市场参与者包括 Abbott Laboratories、Bioventus Inc.、Boston Scientific Corporation、Helius Medical Technologies、Integer Holdings Corporation、LivaNova PLC、Medtronic plc、MicroTransponder Inc.、Neuronetics、NeuroPace Inc.、NeuroSigma Inc.、内夫罗公司等

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

顶级神经调节公司致力于透过合併、收购和合作等策略性措施来增强其竞争优势。他们正在投资研发 (R&D)，以创新和改进其神经调节设备。这些创新的重点是提高慢性疼痛、帕金森氏症和泌尿系统疾病等疾病治疗的准确性、有效性和安全性。此外，产业领导者参与临床试验，以扩大现有技术的适应症，从而扩大潜在的用户群。他们还优先考虑在新市场获得监管批准，以确保全球获得其先进疗法。此外，大公司正在透过数位平台加强患者和从业者的参与，以促进更好地监测和管理治疗结果。这有助于他们适应医疗技术数位健康解决方案的更广泛趋势，从而对神经调节市场的近期发展和机会产生积极影响。

神经调节市场新闻：

2022 年 4 月，波士顿科学公司（美国）的 Vercise Neural Navigator 和视觉化软体 STIMVIEW XT 获得 FDA 批准。该设备可让医疗专业人员查看帕金森氏症患者和接受深部脑部刺激（DBS）患者的引线或电极的即时位置。

2022 年 12 月，雅培实验室的 Eterna 脊髓刺激 (SCS) 系统获得 FDA 批准。它是一种小型植入式可充电脊髓刺激器，用于治疗慢性疼痛。此神经调节装置利用 Abbott 专有的低剂量 BurstDR 刺激。

本报告回答的关键问题：

  • 迄今为止，全球神经调节市场表现如何，未来几年将如何表现？
  • 全球神经调节市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球神经调节市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的神经调节市场？
  • 什么是基于技术的市场分割？
  • 神经调节市场上最具吸引力的技术是什么？
  • 基于生物材料的市场区隔是什么？
  • 神经调节市场上最具吸引力的生物材料是什么？
  • 基于应用程式的市场区隔是什么？
  • 神经调节市场中最具吸引力的应用是什么？
  • 市场竞争结构如何？
  • 全球神经调节市场的主要参与者/公司有哪些？

本报告回答的关键问题：

  • 迄今为止，全球神经调节市场表现如何，未来几年将如何表现？
  • 全球神经调节市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球神经调节市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的神经调节市场？
  • 什么是基于技术的市场分割？
  • 神经调节市场上最具吸引力的技术是什么？
  • 基于生物材料的市场区隔是什么？
  • 神经调节市场上最具吸引力的生物材料是什么？
  • 基于应用程式的市场区隔是什么？
  • 神经调节市场中最具吸引力的应用是什么？
  • 市场竞争结构如何？
  • 全球神经调节市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球神经调节市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依技术

  • 内部神经调节
    • 市场走向
    • 关键环节
      • 脊髓刺激 (SCS)
      • 深部脑部刺激 (DBS)
      • 迷走神经刺激 (VNS)
      • 荐神经刺激 (SNS)
      • 胃电刺激 (GES)
    • 市场预测
  • 外部神经调节
    • 市场走向
    • 关键环节
      • 经皮电神经刺激 (TENS)
      • 经颅磁刺激 (TMS)
      • 其他的
    • 市场预测

第 7 章：市场区隔：依生物材料

  • 金属生物材料
    • 市场走向
    • 市场预测
  • 高分子生物材料
    • 市场走向
    • 市场预测
  • 陶瓷生物材料
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按应用

  • 帕金森氏症
    • 市场走向
    • 市场预测
  • 癫痫
    • 市场走向
    • 市场预测
  • 沮丧
    • 市场走向
    • 市场预测
  • 肌张力失调
    • 市场走向
    • 市场预测
  • 疼痛管理
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Bioventus Inc.
    • Boston Scientific Corporation
    • Helius Medical Technologies
    • Integer Holdings Corporation
    • LivaNova PLC
    • Medtronic plc
    • MicroTransponder Inc.
    • Neuronetics
    • NeuroPace Inc.
    • NeuroSigma Inc.
    • Nevro Corp.
Product Code: SR112024A5722

The global neuromodulation market size reached US$ 7.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.7% during 2024-2032. The market is experiencing robust growth, driven by the increasing prevalence of chronic and neurological disorders, imposition of favorable regulatory environment, rising expenditure on healthcare, significant advancements in device technology, and growing demand for minimally invasive (MI) therapies, supported by strong investment in research and development (R&D) initiatives.

Neuromodulation Market Analysis:

Major Market Drivers: The neuromodulation market is driven by the increasing prevalence of chronic diseases and neurological disorders, such as Parkinson's disease, chronic pain, and depression. Moreover, the rising expenditure on healthcare, the implementation of favorable regulations that offer improvements in reimbursement policies, and rapid technological advancements in neuromodulation devices, including the development of magnetic resonance imaging (MRI)-safe and rechargeable devices, are boosting the market growth.

Key Market Trends: There is a trend towards the integration of artificial intelligence (AI) and machine learning (ML) technologies into neuromodulation devices that enable real-time monitoring and adjustments of therapy. Moreover, the expansion of indications for neuromodulation therapies, facilitated by ongoing research and successful clinical trials, is broadening the market expansion.

Geographical Trends: North America dominates the neuromodulation market due to its advanced healthcare infrastructure, robust regulatory framework, and high healthcare expenditure. Other regions are also experiencing rapid growth, driven by improving healthcare infrastructures, increasing disposable incomes, and growing awareness of neuromodulation therapies.

Competitive Landscape: Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., and Nevro Corp., among many others.

Challenges and Opportunities: A major challenge is the high cost of devices and procedures, which can limit market penetration, especially in developing regions. Additionally, the complexity of device implantation and potential side effects pose hurdles. However, opportunities lie in the expanding scope of neuromodulation applications, including potential treatments for untapped medical conditions, such as obesity and addiction. Furthermore, increasing healthcare spending presents a significant opportunity for market expansion into previously underserved areas.

Neuromodulation Market Trends:

Rising Prevalence of Chronic Diseases and Neurological Disorders

The heightened incidence of chronic diseases such as diabetes, obesity, and cardiovascular conditions, alongside neurological disorders like Parkinson's disease, epilepsy, and depression, is a significant driver for the neuromodulation market. As per the Centre for Disease Control and Prevention (CDC), 6 in 10 adults in the U.S. are suffering from chronic diseases. And 4 out of 10 people have more than two chronic conditions. Also, about 21% of the geriatric adults in India have at least one chronic disease. 17% of geriatric people in rural areas and 29% in urban areas suffer from at least one chronic disease. These health issues lead to complications that can be managed or treated through neuromodulation therapies. For instance, spinal cord stimulation (SCS) is widely used for pain relief in conditions that result from failed back surgery syndrome or complex regional pain syndrome.

Increasing Expenditure on Healthcare

Several countries across the globe are witnessing increased adoption of neuromodulation therapies owing to rising expenditure on healthcare, the growing population of the middle class, and the establishment of advanced healthcare infrastructures. For instance, India's public expenditure on healthcare touched 2.1% of GDP in FY23 and 2.2% in FY22. Also, the Indian government is planning to introduce a credit incentive program worth Rs. 50,000 crores (US$ 6.8 billion) to boost the country's healthcare infrastructure. Similarly, in Europe, the general government spending on health amounted to €1221 billion or 7.7% of GDP in 2022. The U.S. healthcare spending saw a hike of 4.1%, reaching $4.5 trillion or $13493/person. This expansion is increasing the geographical footprint of the neuromodulation industry and introducing these advanced therapies to new patient populations.

Implementation of Favorable Reimbursement Policies

The ongoing improvements in reimbursement policies for neuromodulation procedures is a main factor driving the market growth. In many countries, health insurance providers have revised their policies to include several neuromodulation therapies as they recognize their benefits in treating many refractory conditions. These changes have made neuromodulation technologies more accessible to a broader range of patients. In 2022, 92.1 percent of people, or 304.0 million in the U.S., had health insurance at some point during the year, as per the U.S. Census Bureau. Moreover, private health insurance coverage was more prevalent than public coverage, at 65.6 percent and 36.1 percent, respectively. Also, insurers are recognizing the cost-effectiveness of neuromodulation in the long term, especially in terms of reduced hospital stays and medication use, which is expanding the scope of reimbursement coverage.

Neuromodulation Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on technology, biomaterial, and application.

Breakup by Technology:

Internal Neuromodulation

Spinal Cord Stimulation (SCS)

Deep Brain Stimulation (DBS)

Vagus Nerve Stimulation (VNS)

Sacral Nerve Stimulation (SNS)

Gastric Electrical Stimulation (GES)

External Neuromodulation

Transcutaneous Electrical Nerve Stimulation (TENS)

Transcranial Magnetic Stimulation (TMS)

Others

Internal neuromodulation accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the technology. This includes internal neuromodulation (spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES)) and external neuromodulation (transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS), and others). According to the report, internal neuromodulation represented the largest segment.

Based on the neuromodulation market analysis and forecast, internal neuromodulation emerged as the largest segment. It includes advanced therapies, such as spinal cord stimulation (SCS), deep brain stimulation (DBS), sacral nerve stimulation (SNS), and vagus nerve stimulation (VNS), among others. They are utilized for treating a wide range of chronic conditions and neurological disorders, including chronic pain, Parkinson's disease, urinary and fecal incontinence, and refractory epilepsy. Moreover, the proven efficacy of internal neuromodulations in improving patient outcomes, significant advancements in device technology that enhance user safety and comfort, and the broadening scope of clinical applications are fueling the neuromodulation market revenue.

Breakup by Biomaterial:

Metallic Biomaterials

Polymeric Biomaterials

Ceramic Biomaterials

Metallic biomaterials hold the largest share of the industry

A detailed breakup and analysis of the market based on the biomaterial have also been provided in the report. This includes metallic biomaterials, polymeric biomaterials, and ceramic biomaterials. According to the report, metallic biomaterials accounted for the largest market share.

As per the neuromodulation market report and overview, metallic biomaterials stand out as the largest segment, owing to their critical role in the manufacturing of implants and devices used in neuromodulation therapies, such as electrodes and leads. Metallic biomaterials are favored for their superior electrical conductivity, biocompatibility, and durability. They are essential for ensuring the long-term reliability and performance of neuromodulation devices, particularly those that require chronic implantation or are subject to bodily fluids and tissues. Besides this, the ongoing advancements that improve their functionality and safety, such as coatings to enhance biocompatibility or technologies to reduce the risk of infection, are favoring the neuromodulation market growth.

Breakup by Application:

Parkinson's Disease

Epilepsy

Depression

Dystonia

Pain Management

Others

Parkinson's disease represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes Parkinson's disease, epilepsy, depression, dystonia, pain management, and others. According to the report, Parkinson's disease represented the largest segment.

According to the neuromodulation market outlook and trends, Parkinson's disease emerged as the largest segment, reflecting the significant impact and utility of neuromodulation therapies in managing chronic neurological disorders. The increasing utilization of deep brain stimulation (DBS) for the treatment of patients who do not respond adequately to pharmacological treatments is enhancing the market growth. DBS helps in alleviating symptoms such as tremors, rigidity, and bradykinesia, significantly enhancing the quality of life for patients. Moreover, the efficacy of neuromodulation in providing substantial and sustained symptom relief, leading to its widespread adoption in clinical settings, is catalyzing the neuromodulation market share.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest neuromodulation market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for neuromodulation.

North America accounted for the largest segment in the neuromodulation market, attributed to several key factors, including advanced healthcare infrastructure, strong regulatory support, and substantial investments in research and development (R&D). Moreover, the region is a hub of some of the leading companies in the neuromodulation industry, which drives innovation and market growth through continuous advancements in technology. Additionally, the high prevalence of chronic diseases and neurological disorders, coupled with a well-established healthcare system that facilitates early adoption of new technologies, is contributing to the neuromodulation market revenue.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., Nevro Corp., etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The top neuromodulation companies are engaged in enhancing their competitive edge through strategic initiatives, such as mergers, acquisitions, and partnerships. They are investing in research and development (R&D) to innovate and improve their neuromodulation devices. These innovations focus on increasing the precision, effectiveness, and safety of therapies for conditions like chronic pain, Parkinson's disease, and urinary disorders. Additionally, industry leaders are involved in clinical trials to expand the indications for existing technologies, thereby broadening the potential user base. They are also prioritizing obtaining regulatory approvals in new markets to ensure global access to their advanced therapies. Furthermore, major companies are enhancing patient and practitioner engagement through digital platforms that facilitate better monitoring and management of therapy outcomes. This helps them align with the broader trend toward digital health solutions in medical technology, thereby positively impacting the neuromodulation market's recent development and opportunities.

Neuromodulation Market News:

In April 2022, Boston Scientific Corporation (US) received FDA approval for its Vercise Neural Navigator with visualization software, STIMVIEW XT. The device allows medical professionals to view the real-time location of leads, or electrodes, in patients with Parkinson's disease and those undergoing deep brain stimulation (DBS).

In December 2022, Abbott Laboratories received FDA approval for its Eterna spinal cord stimulation (SCS) system. It is a small implantable and rechargeable spinal cord stimulator for treating chronic pain. The neuromodulation device utilizes Abbott's proprietary low-dose BurstDR stimulation.

Key Questions Answered in This Report:

  • How has the global neuromodulation market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global neuromodulation market?
  • What is the impact of each driver, restraint, and opportunity on the global neuromodulation market?
  • What are the key regional markets?
  • Which countries represent the most attractive neuromodulation market?
  • What is the breakup of the market based on technology?
  • Which is the most attractive technology in the neuromodulation market?
  • What is the breakup of the market based on biomaterial?
  • Which is the most attractive biomaterial in the neuromodulation market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the neuromodulation market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global neuromodulation market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neuromodulation Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Internal Neuromodulation
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Spinal Cord Stimulation (SCS)
      • 6.1.2.2 Deep Brain Stimulation (DBS)
      • 6.1.2.3 Vagus Nerve Stimulation (VNS)
      • 6.1.2.4 Sacral Nerve Stimulation (SNS)
      • 6.1.2.5 Gastric Electrical Stimulation (GES)
    • 6.1.3 Market Forecast
  • 6.2 External Neuromodulation
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
      • 6.2.2.2 Transcranial Magnetic Stimulation (TMS)
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Biomaterial

  • 7.1 Metallic Biomaterials
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymeric Biomaterials
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Ceramic Biomaterials
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Parkinson's Disease
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Epilepsy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Depression
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Dystonia
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Pain Management
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bioventus Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Boston Scientific Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Helius Medical Technologies
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Integer Holdings Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 LivaNova PLC
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Medtronic plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 MicroTransponder Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Neuronetics
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 NeuroPace Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 NeuroSigma Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Nevro Corp.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials

List of Figures

  • Figure 1: Global: Neuromodulation Market: Major Drivers and Challenges
  • Figure 2: Global: Neuromodulation Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Neuromodulation Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Neuromodulation Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Neuromodulation Market: Breakup by Biomaterial (in %), 2023
  • Figure 6: Global: Neuromodulation Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Neuromodulation Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Neuromodulation (Internal Neuromodulation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Neuromodulation (Internal Neuromodulation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Neuromodulation (External Neuromodulation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Neuromodulation (External Neuromodulation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Neuromodulation (Metallic Biomaterials) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Neuromodulation (Metallic Biomaterials) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Neuromodulation (Polymeric Biomaterials) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Neuromodulation (Polymeric Biomaterials) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Neuromodulation (Ceramic Biomaterials) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Neuromodulation (Ceramic Biomaterials) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Neuromodulation (Parkinson's Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Neuromodulation (Parkinson's Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Neuromodulation (Epilepsy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Neuromodulation (Epilepsy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Neuromodulation (Depression) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Neuromodulation (Depression) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Neuromodulation (Dystonia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Neuromodulation (Dystonia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Neuromodulation (Pain Management) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Neuromodulation (Pain Management) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Neuromodulation (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Neuromodulation (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Neuromodulation Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Neuromodulation Industry: SWOT Analysis
  • Figure 80: Global: Neuromodulation Industry: Value Chain Analysis
  • Figure 81: Global: Neuromodulation Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neuromodulation Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Neuromodulation Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Neuromodulation Market Forecast: Breakup by Biomaterial (in Million US$), 2024-2032
  • Table 4: Global: Neuromodulation Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Neuromodulation Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Neuromodulation Market: Competitive Structure
  • Table 7: Global: Neuromodulation Market: Key Players